Illumina

Illumina is a publicly traded life-sciences and biotechnology company headquartered in San Diego, California. Founded in 1998, it developed into one of the central technology suppliers for modern genomics by commercializing high-throughput next-generation sequencing, or NGS, systems and the reagents, library-preparation products, informatics, and services required to operate them. Its platforms are used by academic laboratories, pharmaceutical and biotechnology companies, hospitals, clinical laboratories, public-health agencies, agricultural researchers, and consumer-genomics businesses. The company’s business model combines instrument placements with recurring sales of sequencing consumables and associated software and services. Its sequencing portfolio has included the MiSeq, NextSeq, HiSeq, NovaSeq, and NovaSeq X families, ranging from compact systems for targeted or smaller-scale projects to high-throughput instruments intended for population-scale whole-genome sequencing and other large studies. Illumina’s technology is based on sequencing-by-synthesis and has been applied to whole-genome and exome sequencing, RNA sequencing, single-cell analysis, cancer research, reproductive-health testing, infectious-disease surveillance, and other genomic workflows. The company also supplies microarray products and computational tools such as DRAGEN for secondary analysis of sequencing data. Illumina’s growth was accelerated by its 2007 acquisition of Solexa, whose sequencing technology became a foundation of the company’s dominant NGS franchise. Other acquisitions expanded its capabilities in oligonucleotide synthesis, sample preparation, informatics, and molecular analysis. The company has marketed sequencing as both a research platform and an enabling infrastructure for precision medicine, emphasizing scientific publications, conferences, customer collaborations, demonstrations, and educational content rather than mass-market advertising. Illumina has also pursued clinical and multiomics opportunities. It formed GRAIL as a cancer-screening venture in 2016, later agreed to reacquire the business, and ultimately divested GRAIL in 2024 following regulatory conflict over the transaction. In proteomics, Illumina collaborated with SomaLogic from 2021 and announced an agreement to acquire SomaLogic in 2025, with the transaction reported as completed in January 2026. The deal was intended to connect SomaLogic’s protein-measurement technology with Illumina’s sequencing ecosystem and broader multiomics strategy. The company remains best known for sequencing instruments and consumables, but its strategic scope includes clinical genomics, software, data analysis, proteomics, and integrated multiomics workflows. Its position reflects a large installed base, extensive researcher familiarity, high switching costs, and a substantial ecosystem of protocols and published applications. At the same time, Illumina faces competition from other sequencing technologies, pressure to make advanced sequencing more affordable, regulatory scrutiny of acquisitions, and the challenge of translating research platforms into routine clinical use.

Illumina was established in 1998 by a group including David Walt, Larry Bock, John Stuelpnagel, Anthony Czarnik, and Mark Chee. The company initially focused on array-based genomic analysis and related technologies. In 1999 it acquired Spyder Instruments, gaining high-throughput oligonucleotide-synthesis technology, and it completed an initial public offering in July 2000. A decisive turning point came in January 2007, when Illumina acquired Solexa for approximately $650 million. Solexa had originated from sequencing research by Shankar Balasubramanian and David Klenerman at the University of Cambridge. Its sequencing-by-synthesis approach provided the technological foundation for Illumina’s later high-throughput platforms and helped the company become a major supplier of research sequencing systems. Illumina subsequently broadened its portfolio through the acquisition of Epicentre Biotechnologies in 2011, adding capabilities in sample preparation and molecular biology. In 2012 Roche made an unsolicited proposal to acquire Illumina. Roche raised its offer during the process, but Illumina rejected the bids and Roche abandoned the attempt in April of that year. Remaining independent allowed Illumina to continue investing in sequencing platforms, consumables, informatics, and applications. In 2014 the company introduced the HiSeq X Ten system, aimed at making large-scale whole-genome sequencing more economical. During this period Illumina’s systems accounted for a very large share of sequencing output and were widely adopted by research institutions and clinical-development organizations. The company expanded beyond core research sequencing through software, clinical partnerships, and strategic investments. It invested in Enancio, whose compression technology was intended to reduce the storage burden associated with large sequencing datasets. Illumina also created GRAIL in 2016 as a separate company pursuing blood-based early cancer detection. In 2020 Illumina announced an agreement to reacquire the approximately 85 percent of GRAIL that it did not already own in a transaction valued at about $8 billion. The deal attracted significant regulatory scrutiny, especially in the United States and Europe, because authorities argued that Illumina could disadvantage competing cancer-test developers that relied on Illumina sequencing technology. Illumina ultimately completed the divestiture of GRAIL in June 2024, leaving GRAIL as an independent public company. During the 2020s Illumina introduced the NovaSeq X generation and emphasized lower cost per genome, higher throughput, and improved sustainability. It also pursued a multiomics strategy combining genomic information with other molecular measurements. Illumina and SomaLogic entered a proteomics co-development relationship in late 2021 to bring the SomaScan assay to Illumina sequencing platforms. In June 2025 Illumina announced an agreement to acquire SomaLogic and specified assets from Standard BioTools for cash consideration of $350 million at closing, plus potential performance-based payments and royalties. Illumina announced that the acquisition was completed on January 30, 2026. The transaction extended the company’s activities into proteomics and was presented as a way to connect scalable protein analysis with sequencing, DRAGEN analytics, and connected multiomics workflows. Today Illumina’s core business remains the development and commercialization of NGS instruments, consumables, arrays, software, and related services. Its customers use these products in research, clinical testing, oncology, reproductive health, infectious-disease monitoring, agriculture, and population genomics. The company’s long-term opportunity is tied to broader adoption of genomic and multiomic analysis, while its principal challenges include intense technological competition, regulatory oversight, reimbursement and clinical-validation barriers, capital costs for customers, and the need to preserve an open ecosystem while expanding into adjacent markets.

1. 2026SomaLogic acquisition completed

   Illumina announces completion of the SomaLogic acquisition.

   Source
2. 2025SomaLogic acquisition announced

   Illumina agrees to acquire SomaLogic to strengthen its proteomics and multiomics strategy.

   Source
3. 2024GRAIL divestiture completed

   Illumina completes the spin-off of GRAIL as an independent public company.

   Source
4. 2020Agreement to reacquire GRAIL

   Illumina announces an approximately $8 billion transaction to acquire the portion of GRAIL it did not already own.

   Source
5. 2016GRAIL is spun out

   Illumina establishes GRAIL as a separate venture focused on blood-based cancer detection.

   Source
6. 2014HiSeq X Ten launch

   Illumina announces the HiSeq X Ten system for high-throughput whole-genome sequencing.

   Source
7. 2011Epicentre acquisition

   Illumina acquires Epicentre Biotechnologies to expand molecular-biology and sample-preparation capabilities.

   Source
8. 2007Solexa acquisition

   Illumina completes the acquisition of Solexa, bringing sequencing-by-synthesis technology into the company’s platform portfolio.

   Source
9. 2000Initial public offering

   Illumina completes its initial public offering in July.

   Source
10. 1999Spyder Instruments acquisition

    Illumina acquires Spyder Instruments and adds high-throughput oligonucleotide-synthesis capabilities.

    Source
11. 1998Illumina is founded

    Illumina is established in the United States to develop genomic analysis technologies.

    Source

A leading enabling-technology provider for high-throughput genomics, precision medicine, population-scale sequencing, and increasingly integrated multiomics.

• NovaSeq X SeriesHigh-throughput DNA sequencing2022

  Illumina’s high-throughput sequencing generation for large genomic studies. The platform is positioned for whole-genome sequencing, population projects, oncology research, and other applications requiring substantial output and lower cost per data unit. It is supported by a recurring consumables model and integrates with Illumina’s library-preparation and informatics workflows.

• NovaSeq SeriesHigh-throughput DNA sequencing2017

  The NovaSeq family provides scalable sequencing capacity for laboratories running large research, clinical-development, and population-genomics workloads. It occupies the high-throughput end of Illumina’s portfolio and is designed to support multiple read configurations and project sizes through instrument and consumable choices.

• NextSeq SeriesMid-throughput DNA sequencing2014

  NextSeq instruments are intended for laboratories needing more capacity than a compact benchtop system but not the output of a large production sequencer. They support applications including exome sequencing, RNA sequencing, targeted sequencing, and smaller whole-genome studies.

• MiSeq SeriesBenchtop DNA sequencing2011

  MiSeq systems are compact sequencers used for targeted sequencing, microbial genomics, amplicon analysis, and other projects requiring relatively modest throughput and rapid turnaround. Their smaller laboratory footprint has made them suitable for decentralized research and specialized workflows.

• HiSeq SeriesHigh-throughput DNA sequencing

  The HiSeq family represented an important stage in Illumina’s expansion of high-throughput sequencing. These instruments served whole-genome, exome, transcriptome, and other research applications before newer NovaSeq-generation systems became the company’s principal high-output platform.

• DRAGEN Bio-IT PlatformGenomic data analysis software

  DRAGEN is Illumina’s computational platform for secondary analysis of sequencing data. It is designed to accelerate workflows such as alignment, variant calling, small-variant detection, structural-variant analysis, and other genomic analyses, helping customers convert instrument output into interpretable results.

• Illumina microarraysGenotyping and genomic analysis

  Illumina’s array products measure selected genetic variants and other genomic features at scale. They are used in genotyping, population studies, agricultural research, expression analysis, and other applications where a defined set of markers can provide an efficient alternative or complement to sequencing.

• 2014Illumina Home Page / NextSeq 500 online campaign

  International digital marketing

  An online advertising campaign promoted the NextSeq 500 system and its appeal to researchers seeking whole-genome sequencing capability in a desktop-oriented format.

  Outcome. The campaign received the 2014 Internet Advertising Competition awards for Best Biotechnology Online Campaign and Best Technology Online Campaign.

  Source
• Genomics education and concept-selling program

  Global research and clinical markets

  Illumina uses scientific content, conference activity, professional video and print materials, customer stories, and product-family communications to explain sequencing applications while presenting its instruments and workflows as an integrated portfolio.

  Outcome. The available reference describes the program as supporting professional education and demand generation, but does not provide independently verified performance figures.

  Source

• 2025Agree to acquire SomaLogicM&A

  Illumina’s multiomics strategy called for broader access to proteomics and integration of protein measurements with genomic data.

  What changed. Illumina agreed to acquire SomaLogic and specified assets from Standard BioTools.

  Aftermath. The transaction was presented as a way to combine SomaScan proteomics with Illumina sequencing, DRAGEN analysis, and connected multiomics workflows.

  Cash consideration at closing. $350 million, plus up to $75 million in near-term performance-based milestones and performance-based royalties (2025 agreement)

  Source
• 2024Divest GRAILStrategy

  The divestiture followed regulatory challenges to Illumina’s ownership of GRAIL and the company’s decision to separate the cancer-screening business.

  What changed. Illumina completed a spin-off that made GRAIL an independent public company.

  Aftermath. GRAIL began trading independently under the ticker GRAL, while Illumina retained its core sequencing and multiomics businesses.

  Source
• 2020Agree to reacquire GRAILM&A

  Illumina sought to bring its former cancer-screening venture back into the company before GRAIL’s planned public offering.

  What changed. Illumina announced a cash-and-stock transaction for the approximately 85 percent of GRAIL that it did not already own.

  Aftermath. The transaction generated extended regulatory opposition and was followed by GRAIL’s eventual spin-off in 2024.

  Announced transaction value. Approximately $8 billion (2020)

  Source
• 2012Reject Roche takeover proposalOther

  Roche made an unsolicited proposal to acquire Illumina and later increased its offer.

  What changed. Illumina rejected the proposals, and Roche abandoned the effort in April 2012.

  Aftermath. Illumina remained independent and continued developing its sequencing platform business.

  • Roche — Roche raised its proposal during the takeover attempt before withdrawing it.
  Source
• 2007Acquire SolexaM&A

  Illumina sought a stronger position in next-generation sequencing by acquiring Solexa and its sequencing-by-synthesis technology.

  What changed. Illumina completed the acquisition in January 2007.

  Aftermath. Solexa technology became a foundation of Illumina’s high-throughput sequencing franchise.

  Acquisition consideration. Approximately $650 million (2007)

  Source

• 2020Regulatory dispute over GRAIL acquisitionControversy

  Illumina’s proposed reacquisition of GRAIL prompted regulatory scrutiny in the United States and Europe. Authorities raised concerns that Illumina could restrict or disadvantage rival cancer-test developers that depended on its sequencing technology. Illumina later completed the divestiture of GRAIL in 2024.

  Source

• 2026Illumina completes acquisition of SomaLogic

  Illumina announced completion of the SomaLogic acquisition, combining proteomics technology with its NGS ecosystem and DRAGEN software.

  M&A
  Source
• 2025Illumina announces agreement to acquire SomaLogic

  The proposed acquisition was designed to add SomaLogic’s proteomics capabilities to Illumina’s sequencing and multiomics portfolio.

  M&A
  Source
• 2024Illumina completes the divestiture of GRAIL

  Illumina completed the spin-off of GRAIL, which became an independent publicly traded company under the ticker GRAL.

  M&ARegulation
  Source

1. Illumina, Inc. history reference
2. Illumina leadership
3. Illumina completes the divestiture of GRAIL
4. Illumina to acquire SomaLogic
5. Illumina completes acquisition of SomaLogic
6. 2014 Internet Advertising Competition award
7. GRAIL is spun out
8. Genomics education and concept-selling program